Method: In this retrospective study, data was reviewed from 75 medical charts of 243 patients with primary epithelial ovarian cancers as a preliminary study. All patients underwent chemotherapy and cytoreductive surgery for primary disease. Fifty-six patients had complete response (CR) to chemotherapy and 19 had incomplete response (IR)
.
Materials and Methods

Study design
Patients with primary epithelial ovarian cancers diagnosed by tumor histological analysis and treated at the Department of Gynecologic Oncology at the University of Iowa Hospital and Clinics from January 1991 to December 2013 were eligible for inclusion in this retrospective study. All patients underwent chemotherapy and surgical cytoreduction for primary disease.
Institutional Review Board approval was obtained and a total of 243 patients were eligible for this study. Data was collected from medical charts of 75 patients (median age of 59 years ranging from 25 -83 years) during July 27, 2015 to August 21, 2015 as a preliminary study to determine the viability of this research. Fifty-six patients had complete response and 19 had incomplete response to treatment, defined as evidence of disease within 6 months. Fifty-eight patients had optimal cytoreductive surgery and 17 had suboptimal surgery. Forty-nine (65.3%) patients had recurrence of disease, and 58 (77.3%) patients died. Clinical and pathology findings included age at diagnosis, body mass index, Charlson comorbidity index, FIGO stage, tumor cell type, tumor grade, preoperative CA125, imaging modality at diagnosis, and tumor location (Table 1) . Imaging modalities used were CT, ultrasound, MRI, and PET scans. None of the patients in this cohort received PET scans, 2 had MRIs and 11 had none of the four options. These patients were included under "other." Treatment data included chemotherapy drug, number of cycles, removal of pelvic or para-aortic nodes at surgery, and whether the patient received optimal treatment ( Table 2) .
Patient outcome was assessed by vital status, tumor status, time until recurrence, and time until death (Tables 3-4). The Kaplan-Meier method was used to construct survival curves for overall survival (OS), cancer-specific survival (CSS), and time to recurrence (TTR) (Figure 1 ). For OS, time was calculated from date of surgery to death. Patients still alive were censored at date of last contact. For CSS, time was calculated from date of surgery to date of death due to disease. Patients still alive or having died from other causes were censored at date of last contact or death. respectively. For TTR, time was calculated from date of surgery to first relapse. If a patient did not experience a relapse, they were considered censored at date of last contact.
Statistical Analysis
To investigate treatment response and cytoreduction surgery differences in demographic, clinicopathologic, and outcome variables, chi-squared and ttests (Fisher's exact and Wilcoxon rank sum tests where appropriate) were used. The Kaplan-Meier method was used to construct survival curves for overall survival (OS), cancer-specific survival (CSS), and time to recurrence (TTR) as aforementioned. The log-rank test was performed to assess for differences between treatment response and cytoreduction surgery. All statistical testing was two-sided and assessed for significance at the 5% level using SAS v9.4 (SAS Institute, Cary, NC).
Results
Characteristics of patients with complete and incomplete response to chemotherapy
This study included 75 patients, and the clinical characteristics and pathology findings of these patients are found in Table 1 . Fifty-six (74.7%) patients had complete response (CR) and 19 (25.3%) had incomplete response (IR) to chemotherapy. At diagnosis, patients had a mean age of 58.3 ± 12.9 years, median body mass index of 26 (range: 16.5-47.8), and median Charlson index of 5 (range: 1-10). A significant difference was evidenced between treatment response and preoperative CA125. More specifically, patients achieving a CR had lower median preoperative CA125 levels compared to those with an IR (362.5 U/mL vs. 771.0 U/mL; p = 0.03). One patient had a preoperative CA125 of 588,741 U/mL, a significant outlier, and was excluded from the analysis. In terms of treatment as outlined in Table 2 , both CR and IR groups had a median of 6 cycles of chemotherapy. In both CR and IR groups, the majority of patients died from ovarian cancer. However, significantly more patients with IR died from the disease than patients who had CR (94.7% vs. 56.4%, p < 0.01). More patients in the CR group are alive or dead from causes other than ovarian cancer (p <0.01). Thirty-five (62.5%) patients with CR had recurrence of disease and a median time to recurrence of 18.7 months (range: 8.9-81.5). The majority (73.6%) of patients with IR had recurrence; however the median time was 6.9 months (range 4.3-28.6). Patients in CR group had a longer time until first recurrence of disease than the IR group (p < 0.01). Additionally, the survival was significantly longer for patients with CR than patients with IR (p < 0.01).
Regarding surgical treatment, 58 (77.3%) and 17 (22.7%) patients had optimal (OPS) and suboptimal (SOS) cytoreductive surgery, respectively, as shown in Table 4 . The majority had tumor present after primary therapy for both groups. Nevertheless, significantly 
Survival analysis
The Kaplan-Meier analyses to assess overall survival (OS), cancer-specific survival (CSS), and time to recurrence (TTR) are shown in Figures 1 and 2 , and Tables 5 and 6 . Patients who had complete treatment response had significantly increased OS, CSS, and TTR (p < 0.01 for all). Patients who had optimal surgery also had significantly higher OS, CSS, and TTR than patients with suboptimal surgery (p < 0.01 for all). Table 5 . Table 5 . Survival analysis for patients with complete and incomplete response Figure 2 . Kaplan-Meier analysis of overall survival, cancer-specific survival, and time to recurrence between patients with optimal and suboptimal surgery. Significant difference exists between both groups in all three categories (p < 0.01), and median time of survival is presented in Table 6 . Table 6 . Survival analysis for patients with optimal and suboptimal surgery
Discussion
Standard treatment of epithelial ovarian cancer is primary debulking surgery in conjunction with platinum-based chemotherapy. Despite the success of chemotherapy, about one-third of women are either refractory or resistant to treatment. Preoperative CA125 and lymph node removal during surgery were associated with complete treatment response in this preliminary institutional study.
CA125 as a predictor of chemotherapy response
CA125 is a biomarker of epithelial tumors that is useful as a measure for monitoring treatment effectiveness and disease recurrence. It is not recommended as a tool for screening. In our study, preoperative CA125 is a significant predictor of chemotherapy response. Patients with complete response to treatment had significantly lower CA125 at diagnosis, and complete response to treatment had significantly greater overall survival, cancer-specific survival, and time to recurrence. Many studies both support and contradict this finding. A study by Oikonomopoulou et al. agrees that lower baseline CA125 prior to chemotherapy is associated with better chemotherapy response. Higher baseline values had worse OS and PFS. 5 Similarly, Palmer et al. and Juretzka et al. found lower CA125 were more significantly associated with longer overall survival and progression-free survival. 6, 7 Serum CA125 levels correlate with vascular endothelial growth factor (VEGF) expression, which is significantly upregulated in epithelial ovarian cancer, and predicts positive responsiveness to platinum-based chemotherapy. 8 The debate continues as other studies discovered no correlation between preoperative CA125, chemotherapy response, and surgical outcome despite being a validated marker for disease status during chemotherapy. 8, 9, 10 range to determine which patients are at increased risk for incomplete response to chemotherapy is unknown.
Complete chemotherapy response and optimal surgery in controlling disease
Complete response to therapy and optimal cytoreductive surgery are two important factors associated with a decrease in death from disease and longer survival. Over 94% of patients with either incomplete treatment response or suboptimal surgery died from ovarian cancer. This value lowered significantly to less than 60% death from disease those with either complete treatment response or optimal surgery. Additionally, patients with complete treatment or optimal surgery had longer time until death and recurrence, greater overall survival, and greater cancerspecific survival of up to over 5-fold increase. The increase in median survival time and time to recurrence was greater in terms of chemotherapy response than for surgery. Although both surgery and chemotherapy are key components to treating ovarian cancer, this suggests that chemotherapy has a greater role in prolonging survival and recurrence.
Our study also found that patients with complete response to therapy were more likely to have either pelvic and/or para-aortic lymph nodes removed during surgery. The spread of disease to the retroperitoneal lymph nodes is a prominent characteristic of advanced stage ovarian cancer. Although FIGO stage did not differ between the response groups, patients with complete treatment response more frequently had surgery to the nodal areas than patients with an incomplete response. Involvement of the bowel during surgery showed no significant associations with the two response groups. In a recent review by Chang et al. discussing cytoreduction on advanced stage ovarian cancer, aggressive surgery is prognostic of better outcomes, but optimal debulking is dependent on expertise of the surgeon and of the institution. 13 This study was completed at a teaching hospital with a department of gynecologic oncology and specialized surgeons. Therefore, these findings may be specific to this institution.
Limitations
The limitations of this study are due to the retrospective nature of the analysis. Additionally, there may be not sufficient power to establish significances in this preliminary analysis. The incomplete response group represented 25.3% of the patient sample and the suboptimal surgery group represented 22.7%. Thus, the power should increase as more patients are added to this study.
Future direction
The current conflicting clinicopathological data pushes us to look deeper into genomic factors that may help us better understand how to predict chemoresponsiveness. In future studies, we will look at possible molecular predictors. The existing literature has assessed the predictive value of tumor markers such as human epididymis protein 4 (HE4), a glycoprotein overexpressed in serous and endometrioid ovarian cancers. Serum HE4 levels were not found to be a predictor of chemoresponse prior to treatment, but its normalization during treatment was significantly associated with positive outcomes. 9, 14 More recently, Muallem et al. found that the level of ERCC1, a DNA excision repair protein, was significantly associated with better overall survival. Patients who did not respond to platinum-based chemotherapy with low or intermediate ERCC1 levels had a longer overall survival than non-responders with high ERCC1. 15 Steffensen et al. furthermore suggest that high ERCC1 expression is associated with earlier time to recurrence and platinum-resistance. 16 Lastly, other proteins, such as Ecadherin, interferon regularly factor 1 (IRF1), and high-temperature-required protein A2 (HtrA2) have been shown to be prognostic and associated with increased response to platinum-based chemotherapy at higher levels of expression. 17, 18, 19 These specific proteins may be subjects of future evaluation in this institutional study.
